Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies
- PMID: 19404957
- DOI: 10.1002/art.24485
Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies
Erratum in
- Arthritis Rheum. 2009 Oct;60(10):3071
Abstract
Objective: To assess the efficacy and safety of VX-702, a p38 MAPK inhibitor, in patients with active, moderate-to-severe rheumatoid arthritis (RA).
Methods: Two 12-week, double-blind, placebo-controlled studies of VX-702 were conducted in patients with active, moderate-to-severe RA. In the VeRA study, 313 patients received placebo or 2 daily doses of VX-702. In Study 304, 117 patients received placebo, daily VX-702, or twice weekly VX-702 in addition to concomitant methotrexate (MTX). Study end points included the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (an ACR20 response), ACR50 and ACR70 responses, changes in the serum levels of biomarkers of inflammation, and safety assessments.
Results: The numerically superior ACR20 response rates among patients receiving VX-702 compared with those receiving placebo in both studies did not reach pairwise statistical significance at the highest doses in either study. At week 12 in the VeRA study, ACR20 response rates were 40%, 36%, and 28% among patients receiving 10 mg of VX-702, 5 mg of VX-702, and placebo, respectively. In Study 304, the response rates were 40%, 44%, and 22% for patients receiving 10 mg VX-702 daily plus MTX, 10 mg VX-702 twice weekly plus MTX, and placebo, respectively. Reductions in the levels of C-reactive protein, soluble tumor necrosis factor receptor p55, and serum amyloid A were observed as early as week 1 in both studies, but these levels rapidly returned to baseline values by week 4. The overall frequency of adverse events was similar between the VX-702 and placebo groups. In the VeRA study, serious infections were more frequent in the VX-702 groups compared with the placebo group (2.4% versus 0%) but not in Study 304 (2.6% versus 4.9%).
Conclusion: The modest clinical efficacy plus the transient suppression of biomarkers of inflammation observed in this study suggest that p38 MAPK inhibition may not provide meaningful, sustained suppression of the chronic inflammation seen in RA.
Trial registration: ClinicalTrials.gov NCT00205478 NCT00395577.
Comment in
-
The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese.Arthritis Rheum. 2009 Nov;60(11):3513-4. doi: 10.1002/art.24919. Arthritis Rheum. 2009. PMID: 19877029 No abstract available.
Similar articles
-
Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.Arthritis Rheum. 2009 Feb;60(2):335-44. doi: 10.1002/art.24266. Arthritis Rheum. 2009. PMID: 19180516 Clinical Trial.
-
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.Arthritis Rheumatol. 2016 Jan;68(1):46-55. doi: 10.1002/art.39473. Arthritis Rheumatol. 2016. PMID: 26473751 Clinical Trial.
-
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.Arthritis Rheum. 2010 Apr;62(4):917-28. doi: 10.1002/art.27348. Arthritis Rheum. 2010. PMID: 20131276 Clinical Trial.
-
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.Arthritis Rheum. 2004 May;50(5):1400-11. doi: 10.1002/art.20217. Arthritis Rheum. 2004. PMID: 15146409 Clinical Trial.
-
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.Arthritis Rheum. 2011 Mar;63(3):622-32. doi: 10.1002/art.30194. Arthritis Rheum. 2011. PMID: 21360491 Clinical Trial.
Cited by
-
MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. J Clin Invest. 2024. PMID: 38512415 Free PMC article.
-
Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis.J Pers Med. 2023 Oct 29;13(11):1550. doi: 10.3390/jpm13111550. J Pers Med. 2023. PMID: 38003865 Free PMC article. Review.
-
Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i).Pharmaceuticals (Basel). 2023 Sep 12;16(9):1286. doi: 10.3390/ph16091286. Pharmaceuticals (Basel). 2023. PMID: 37765094 Free PMC article. Review.
-
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9. Signal Transduct Target Ther. 2023. PMID: 36797236 Free PMC article. Review.
-
Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.ACR Open Rheumatol. 2023 Feb;5(2):63-70. doi: 10.1002/acr2.11517. Epub 2023 Jan 5. ACR Open Rheumatol. 2023. PMID: 36604812 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials